Growth Hormone Secretagogues and the Evidence Behind Them
Compare tesamorelin, sermorelin, CJC-1295, ipamorelin and MK-677. Learn what studies found about GH, IGF-1, safety and FDA status.

Growth hormone secretagogues prompt the pituitary to release growth hormone. They act through either the GHRH receptor or the ghrelin receptor. Of the compounds compared here, tesamorelin has a current FDA-approved treatment indication. Studies of several others show hormone changes, while benefits for strength, healthy aging, or general weight loss remain unproven.

How do these compounds differ from growth hormone injections?
A secretagogue asks the pituitary to release its own growth hormone. Recombinant human growth hormone, also called somatropin, supplies the hormone directly. The pituitary normally releases growth hormone in pulses. A medicine can alter the height of those pulses or the amount of hormone circulating between them.
The hypothalamus releases growth hormone-releasing hormone (GHRH), which stimulates pituitary cells called somatotrophs through the GHRH receptor. Somatostatin inhibits release, and growth hormone (GH) and insulin-like growth factor 1 (IGF-1) take part in feedback. The liver makes much of the IGF-1 measured in blood in response to GH. [1, 2]
Ghrelin, made mainly in the stomach, activates the growth hormone secretagogue receptor (GHS-R) in the pituitary and elsewhere. It helps regulate hunger as well as GH release. These pathways interact. Recombinant GH bypasses pituitary release, and its exposure pattern depends on the formulation. Feedback can reduce endogenous secretion, but the route alone cannot establish permanent suppression, relative safety, or cost. [1, 2]
How do sermorelin, tesamorelin and CJC-1295 compare?
All three compounds act through the GHRH pathway. Tesamorelin has phase 3 evidence for reducing visceral fat in adults with HIV-associated lipodystrophy. Sermorelin has a history of FDA approval, and the original products were discontinued. CJC-1295 with DAC raised growth hormone and IGF-1 for days in short studies of healthy adults.
What did the tesamorelin trials measure?
The FDA first approved tesamorelin as Egrifta in 2010 to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. In a pooled analysis of two randomized phase 3 trials involving 806 adults on antiretroviral therapy, the estimated treatment effect on visceral fat at week 26 was a 15.4% reduction relative to placebo (p < 0.001). Imaging measured fat around internal organs. The approval excludes general weight management. [3, 4]
In a separate University of Washington trial, 152 adults aged 55–87 with normal cognition or mild cognitive impairment were randomized to a daily subcutaneous 1 mg study dose or placebo for 20 weeks. The trial tested executive function and verbal and visual memory. Executive function improved (p = 0.005) on a composite that included task switching, Stroop interference timing, self-ordered pointing and word fluency. Verbal memory showed a trend (p = 0.08). This remains a research finding, and tesamorelin has no FDA-approved cognitive indication. [5]
Why was sermorelin used in the past?
Sermorelin reproduces the first 29 amino acids of human GHRH. It briefly stimulates pituitary GH release, with a reported half-life of about 11–12 minutes after subcutaneous administration. Geref formulations were previously approved to assess pituitary GH release and to treat certain children with GH deficiency and growth failure. The manufacturer notified FDA of discontinuation in 2008. FDA later determined that the products were not withdrawn for safety or effectiveness reasons. That finding applies to the historical products. Any compounded sermorelin is a separate, unapproved preparation. [2, 6]
What changes when CJC-1295 has DAC?
The Drug Affinity Complex (DAC) allows the compound to bind circulating albumin. A human study estimated a half-life of 5.8–8.1 days. After one administration, mean GH reached about 2–10 times its baseline level for at least six days, and mean IGF-1 reached about 1.5–3 times baseline for 9–11 days. Trials also studied repeat administrations at weekly or biweekly intervals. Another small study detected GH pulses despite higher trough levels. The long-term effects on pulse amplitude and clinical outcomes remain uncertain. [7–9]
The non-DAC variant is often called modified GRF 1–29. The human duration and biomarker findings above apply to DAC. FDA’s review did not establish a comparable half-life or clinical benefit for the non-DAC form. Neither form has FDA approval. [8–10]
What do ipamorelin, GHRP-2, GHRP-6 and MK-677 do?
These compounds stimulate the ghrelin receptor pathway. Early preclinical work suggests ipamorelin is more selective for growth hormone release than certain older peptides. Human studies show GHRP-2 can increase appetite. Oral MK-677 can raise IGF-1, but it worsened measures of blood sugar control in a randomized trial of older adults.
Ipamorelin produced GH release comparable to GHRP-6 in rat pituitary cells. In pigs, it produced little ACTH or cortisol stimulation compared with GHRP-2 and GHRP-6. These findings do not establish that ipamorelin is free of appetite or hormone effects in people, or that it is better tolerated. FDA identified serious events, including deaths, in a study of intravenous ipamorelin for a different purpose. Whether the drug caused those events is uncertain. [11, 21, 22]
GHRP-6 is an early synthetic GH-releasing peptide described in work published in 1984. Both GHRP-2 and GHRP-6 can trigger substantial GH release in short human studies. Research with GHRP-2 documented increases in prolactin, ACTH and cortisol, as well as food intake. GHRP-6 has also increased ACTH, cortisol and prolactin in human studies, and its ghrelin-receptor activity is relevant to appetite. Direct comparisons are too limited to rank the two for strength, hunger, or tolerability in routine use. [12–15, 20]
MK-677, or ibutamoren, is a nonpeptide oral ghrelin-receptor agonist studied by Merck researchers starting in the 1990s, including in GH deficiency and for muscle and bone outcomes. IGF-1 rose about 40% from baseline in one short study and about 60% at 12 months in a separate older-adult trial. A daily 25 mg dose was used in the latter trial. That was a research dose, and the drug has no FDA-approved regimen. [16–18]
At 12 months, the older-adult trial found a 1.1 kg gain in fat-free mass with MK-677 versus a 0.5 kg loss with placebo. Strength and function did not improve. Fasting glucose rose by about 5 mg/dL, insulin sensitivity declined, and increased appetite and edema were reported. A separate phase 2b hip-fracture study stopped early after a congestive heart failure safety signal. [18, 19]

Does combining two secretagogues improve outcomes?
Small human studies found that GHRH and an older GH-releasing peptide could raise growth hormone more together than either alone. Those studies measured a short-term hormone response. They do not establish clinical benefit, safety, or a preferred formulation for pairing CJC-1295 with ipamorelin for fitness, body composition, or healthy aging.
The proposed combination engages two receptors that influence pituitary GH release. The timing and clinical effects of a specific pairing still need direct study. A preference for the non-DAC variant based on shorter exposure is a hypothesis, and a larger GH rise alone cannot show improved strength, reduced visceral fat, or better health. [9, 10, 20, 21]
How strong is the evidence for each compound?
| Compound | Pathway | What the evidence shows |
|---|---|---|
| Tesamorelin | GHRH receptor | Phase 3 reduction in visceral fat in adults with HIV-associated lipodystrophy. FDA-approved for that population. [3, 4] |
| Sermorelin | GHRH receptor | Short-acting. Original FDA-approved Geref products discontinued. [2, 6] |
| CJC-1295 with DAC | GHRH receptor | Sustained GH and IGF-1 elevation in short studies. Lacks FDA approval. [7–10] |
| CJC-1295 without DAC | GHRH receptor | Limited human evidence. DAC results do not apply. Lacks FDA approval. [10] |
| Ipamorelin | Ghrelin receptor | Selective GH release in preclinical models. Lacks FDA approval. [11, 21] |
| GHRP-2 and GHRP-6 | Ghrelin receptor | Short human studies found GH and other hormone responses. Both lack FDA approval. [13–15, 22] |
| MK-677 | Ghrelin receptor | Oral drug studied in humans. Raised IGF-1 and fasting glucose in an older-adult trial. Lacks FDA approval. [18, 19, 21] |
Oral macimorelin is a separate ghrelin-receptor medicine with FDA approval for diagnosing adult GH deficiency. Its approved use is a diagnostic test. [23]
What do FDA and HHS rules mean for compounding?
FDA drug approval, inclusion on the Section 503A bulk substances list, and federal enforcement discretion are distinct. Advisory committee votes inform rulemaking. An HHS interim policy applies to six named peptides and leaves CJC-1295, ipamorelin and ibutamoren outside its scope. A licensed pharmacy must check the exact ingredient, preparation and applicable requirements.
In October 2024, the FDA Pharmacy Compounding Advisory Committee recommended against adding the reviewed ipamorelin forms and ibutamoren mesylate to the 503A bulks list. In December 2024, it recommended against adding the reviewed CJC-1295 and AOD-9604 forms. FDA identifies CJC-1295 and ipamorelin acetate among withdrawn nominations previously in Category 2. Its May 2026 materials list ibutamoren mesylate in 503A Category 2 and GHRP-2 and GHRP-6 in 503A Category 3. Separately, GHRP-2 (injectable and nasal routes), GHRP-6 and ipamorelin acetate appear on the 503B risk list. [21, 22, 25, 30]
The July 23–24, 2026 committee agenda addressed BPC-157, KPV, TB-500 and MOTS-c on day one and emideltide (DSIP), Semax and Epitalon on day two. Those were separate from the GH secretagogues discussed here. HHS subsequently named six of those substances, excluding emideltide, for conditional interim enforcement discretion. FDA also announced a separate five-substance advisory meeting planned before the end of February 2027, with the date and location still to be scheduled in the notice. [26–28]
For a patient-specific compounded prescription, the treating physician determines the medical need and prescription. The state-licensed dispensing pharmacy is responsible for confirming federal and state requirements, ingredient eligibility and quality controls. FDA does not review compounded medicines for safety, effectiveness or quality before they are marketed. [24, 29]
What should you ask a physician before considering treatment?
Start with the health concern you want to address, such as changes in body composition or low energy. A physician can decide whether GH-related testing is appropriate and look for more likely causes. If tesamorelin is indicated, its prescribing information calls for blood sugar assessment and ongoing IGF-1 monitoring.
1. Ask what the labs can tell you. A single random GH level is hard to interpret because GH peaks and falls during the day. If adult GH deficiency is suspected, an age-adjusted IGF-1 result and often a stimulation test help guide the evaluation. [1]
2. Share your health history. Discuss diabetes risk, pituitary disease or surgery, and any cancer history. Tesamorelin is contraindicated in active malignancy, pregnancy, disruption of the hypothalamic-pituitary axis and known hypersensitivity. The effects of prolonged IGF-1 elevation are uncertain. [3]
3. Agree on what to monitor. If tesamorelin is prescribed, ask how the physician will track meaningful benefit, glucose, IGF-1 and side effects such as swelling or joint pain. The safety plan depends on the specific diagnosis and medication. [1, 3]
Common questions about PEPLIX HEALTH
Peplix Health is a cash-pay telehealth service managed by Monarch Brands LLC. An independent, board-certified physician evaluates symptoms, medical history and available labs. When treatment is appropriate, the physician individualizes the medication, dose and follow-up. A state-licensed pharmacy can fulfill an eligible patient-specific compound under applicable Section 503A and state requirements.
Can tesamorelin help with ordinary weight loss?
Its approved indication is reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. The label excludes general weight management, and long-term cardiovascular safety has not been established. [3]
Can a blood test tell me if I have growth hormone deficiency?
An IGF-1 result can help guide an evaluation in the right clinical setting. A normal result does not rule out deficiency, and most adults with suspected deficiency need a stimulation test. Review the result with a physician who understands your pituitary and overall health history. [1]
Can I request a particular peptide or pharmacy?
You can ask which treatments and dispensing options are available in your state. A visit is an evaluation. The physician decides whether there is a medical indication, and any compounded prescription requires an appropriate preparation and a pharmacy able to fill it under applicable rules. [24, 29]
What should I bring to a Peplix Health telehealth visit?
Bring your medication and supplement list, any recent labs, and a short timeline of changes in energy, weight or body composition. Include past diagnoses, especially pituitary conditions, elevated blood sugar or cancer.
For consultation information, see our longevity guide or start an online assessment.
Medical information notice. This article is educational. Discuss diagnosis, treatment and medication changes with a licensed healthcare professional.
Clinical and regulatory references
Sources
- Endocrine Society. Evaluation and treatment of adult growth hormone deficiency.
- Review. Growth hormone secretagogues and their mechanisms.
- FDA. Egrifta WR U.S. prescribing information.
- Falutz et al. Pooled phase 3 tesamorelin trials in HIV-associated lipodystrophy.
- Baker et al. Randomized trial of a GHRH analog and cognition.
- FDA. Federal Register determination on Geref discontinuation.
- Jetté et al. Albumin conjugation and development of CJC-1295.
- Teichman et al. CJC-1295 hormone responses and half-life in healthy adults.
- Ionescu and Frohman. GH pulsatility during CJC-1295 exposure.
- FDA. Briefing on CJC-1295-related bulk drug substances.
- Raun et al. Preclinical characterization of ipamorelin selectivity.
- Bowers et al. Early study of a synthetic GH-releasing hexapeptide.
- Arvat et al. GHRP-2, prolactin, ACTH and cortisol in humans.
- Laferrère et al. GHRP-2 and food intake in healthy men.
- Frieboes et al. GHRP-6 and GH, ACTH and cortisol release.
- Chapman et al. Oral MK-677 and the GH and IGF-1 axis.
- Murphy et al. MK-677, IGF-1 and bone turnover markers.
- Nass et al. MK-677, body composition and function in older adults.
- Adunsky et al. MK-677 phase 2b trial after hip fracture.
- Bowers et al. Acute GH response to GHRH and a GH-releasing peptide in men.
- FDA. Advisory committee minutes on ipamorelin and ibutamoren, October 2024.
- FDA. Safety risks for certain compounding bulk drug substances.
- FDA. Macrilen U.S. prescribing information.
- FDA. Section 503A bulk substance criteria and nomination categories.
- FDA. Advisory committee minutes on CJC-1295 and AOD-9604, December 2024.
- FDA. July 23–24, 2026 advisory committee agenda and materials.
- HHS. Interim enforcement policy for six peptide bulk drug substances.
- FDA. Advisory meeting planned before the end of February 2027.
- FDA. Compounding questions and answers.
- FDA. Section 503A interim categories, May 2026.


